A retrospective study of 33 patients with advanced PC (17 patients received anlotinib combined with GA regimen (GEM, albumin-bound paclitaxel) and 16 patients received GA regimen alone revealed that the anlotinib combination GA regimen group had significantly improved mOS (9.0months vs 6.0 months, P = 0.006) and mPFS(5.0months vs 2.7months, P = 0.022) when compared with the GA regimen group alone (43). This evidence concerns the gene ALB and pachyonychia congenita.